Amivantamab Plus Lazertinib Added to NCCN for Frontline NSCLC
Panelists discuss the National Comprehensive Cancer Network (NCCN) guidelines for first-line treatment of EGFR-mutant metastatic non–small cell lung cancer (NSCLC), emphasizing the recommended therapies and best practices for patient management.
EP: 1.Overview of MARIPOSA Study
EP: 2.Amivantamab Plus Lazertinib Clinical Efficacy
EP: 3.Safety Considerations for Frontline Amivantamab Plus Lazertinib
Now Viewing
EP: 4.Amivantamab Plus Lazertinib Added to NCCN for Frontline NSCLC
EP: 5.Putting Amivantamab Plus Lazertinib Into Practice
EP: 6.Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC
Recent Videos
